Foresite Capital Opportunity Management V, LLC

10% Owner · Eikon Therapeutics, Inc.

Every open-market stock purchase Foresite Capital Opportunity Management V, LLC has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. Insiders sell for many reasons, but they buy with their own money for one — this page tracks where those buys landed inside insider clusters and how the prices paid compare to where the stock trades now.

Total bought
$41.0M
Open-market buys
3
Companies
2
Last buy
Feb 4, 2026

Where the buys stand today

  • ALMS
    ALUMIS INC.
    +70.4% vs price paid

    2 purchases totalling $40.0M at an average of $16.00 per share; the stock last traded at $27.27. See all insider buying in ALMS

    Avg price paid
    $16.00
    Latest price
    $27.27
    Market cap
    $3.5B
  • EIKN
    Eikon Therapeutics, Inc.
    −31.9% vs price paid

    One purchase totalling $1.0M at an average of $18.00 per share; the stock last traded at $12.25. See all insider buying in EIKN

    Avg price paid
    $18.00
    Latest price
    $12.25
    Market cap
    $663.2M

Cluster participation

Buys that landed within days of other insiders buying the same stock — the pattern this site exists to catch.

All reported buys

DateTickerSharesPriceValueFiling
Feb 4, 2026
EIKNcluster
55,555$18.00$1.0MSEC ↗
Jul 1, 2024
ALMScluster
2,187,500$16.00$35.0MSEC ↗
Jul 1, 2024
ALMScluster
312,500$16.00$5.0MSEC ↗

Get alerted the next time Foresite Capital Opportunity Management V, LLC — or any insider — buys

We watch every Form 4 as it hits SEC EDGAR and alert you when insiders cluster into the same stock.

About this data

Figures are parsed from Foresite Capital Opportunity Management V, LLC's Form 4 filings on SEC EDGAR (CIK 1792207) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.

This page is informational and reflects public filing data. It is not investment advice.